Non B Clade HIV-1 Infections in African and African Immi

非洲和非洲伊米的非 B 分支 HIV-1 感染

• 批准号: 7184258
• 负责人: Barney Scott Graham
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7184258
• 关键词: AIDS vaccines; African; HIV infections; cellular immunity; cytotoxic T lymphocyte; drug resistance; epidemiology; flow cytometry; genotype; human immunodeficiency virus 1; human tissue; immigrant; immune response; mixed tissue /cell culture; phenotype; polymerase chain reaction; stainings; virus classification; virus cytopathogenic effect; virus genetics

The human immunodeficiency virus type 1 (HIV-1) is an emergent virus of great public health significance. The continual evolution of HIV-1 into groups (M, N and O) and, further, into clades has had a tremendous impact on both the efficacy of antiviral therapeutics and the design of HIV/AIDS vaccines. HIV-1 group M viruses are organized genotypically into subtypes or clades alphanumerically designated A through K, with HIV-1 clades A and C accounting for the overwhelming burden of HIV disease globally. While HIV-1 clade C viruses predominate in the Southern and Eastern regions of Africa, throughout India and China, subtype A viruses are primarily found in Western and Central Africa, Central Europe and Thailand. The NIH Vaccine Research Center (VRC) is dedicated to developing HIV/AIDS vaccines that will elicit effective cellular immune responses against HIV-1 clades A, B and C. However, without the guidance of correlates of effective antiviral immunity, either natural or vaccine induced, developing effective vaccines is severely hampered. Accordingly, it is critical that we further our understanding of antiviral cellular immune responses in HIV-1 nonB clade infections, and underlying determinants of nonB clade viral fitness. To address these issues, the HIV section of the Viral Pathogenesis Laboratory (VPL) will examine antiviral cellular immunity in HIV infected African and African immigrant cohorts utilizing intracellular cytokine staining (ICS) FACS-based assays. Cross-clade immunity will be assessed by using peptide pools representing HIV-1 clades A, B and C

人类免疫缺陷病毒1型（HIV-1）是一种具有极大公共健康意义的新兴病毒。 HIV-1分为组（M，N和O）的持续演变以及进化枝的进化，对抗病毒疗法的疗效和HIV/AIDS疫苗的设计都产生了巨大影响。 HIV-1组病毒在基因型中组织成亚型或进化枝，用字母指定为A至K，HIV-1进化枝A和C占全球HIV疾病的压倒性负担。尽管HIV-1进化枝C病毒在非洲南部和东部地区占主导地位，在整个印度和中国，Subtype A病毒主要在西部和中非，中欧和泰国发现。 NIH疫苗研究中心（VRC）致力于开发艾滋病毒/艾滋病疫苗，这些疫苗将引起针对HIV-1进化枝A，B和C的有效细胞免疫反应。但是，如果没有导致自然或疫苗的有效抗病毒免疫相关的指导，即诱导的自然或疫苗，就会受到有效的疫苗的限制。因此，至关重要的是，我们要进一步了解HIV-1 NONB进化膜中的抗病毒细胞免疫反应以及Nonb进化膜病毒适应性的潜在决定因素。为了解决这些问题，病毒发病机理实验室（VPL）的HIV部分将检查使用基于细胞内细胞因子染色（ICS）基于FACS的测定法的HIV感染的非洲和非洲移民同类的抗病毒细胞免疫。将通过使用代表HIV-1进化枝A，B和C的肽池来评估交叉损伤。